These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31679947)

  • 21. Biomarkers: Their Role in CFTR Modulator Therapies from Early Development to the Clinic.
    Bell SC; Wood ME
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1375-1376. PubMed ID: 29406823
    [No Abstract]   [Full Text] [Related]  

  • 22. Tezacaftor/Ivacaftor (Symdeko) for cystic fibrosis.
    Med Lett Drugs Ther; 2018 Oct; 60(1558):174-176. PubMed ID: 30335045
    [No Abstract]   [Full Text] [Related]  

  • 23. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.
    Elborn JS; Ramsey B; Wainwright C; Boyle M
    Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855
    [No Abstract]   [Full Text] [Related]  

  • 24. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 25. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
    Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
    Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
    Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
    Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
    Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS
    Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tezacaftor for the treatment of cystic fibrosis.
    Sala MA; Jain M
    Expert Rev Respir Med; 2018 Sep; 12(9):725-732. PubMed ID: 30073878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cystic fibrosis prognosis in Europa : chronicle of an announced dilemma].
    Lebecque P; Thimmesch M
    Rev Med Liege; 2021 Mar; 76(3):202-207. PubMed ID: 33682390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
    Antoniu SA
    Expert Opin Investig Drugs; 2011 Mar; 20(3):423-5. PubMed ID: 21303308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
    Brewington JJ; McPhail GL; Clancy JP
    Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The stony road to phe508del CFTR pharmacotherapy: smoothing the first rock.
    Tümmler B
    Lancet Respir Med; 2014 Jul; 2(7):508-9. PubMed ID: 24973279
    [No Abstract]   [Full Text] [Related]  

  • 36. [A milestone in cystic fibrosis therapy].
    Reinhardt D
    MMW Fortschr Med; 2015 Nov; 157(19):34. PubMed ID: 26953403
    [No Abstract]   [Full Text] [Related]  

  • 37. Another Beginning for Cystic Fibrosis Therapy.
    Davis PB
    N Engl J Med; 2015 Jul; 373(3):274-6. PubMed ID: 25981385
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.
    Donaldson SH; Solomon GM; Zeitlin PL; Flume PA; Casey A; McCoy K; Zemanick ET; Mandagere A; Troha JM; Shoemaker SA; Chmiel JF; Taylor-Cousar JL
    J Cyst Fibros; 2017 May; 16(3):371-379. PubMed ID: 28209466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new chapter in therapy for cystic fibrosis.
    Bilton D
    Lancet Respir Med; 2015 Jul; 3(7):e20. PubMed ID: 26117158
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.